[Clinical reevaluation of ofloxacin (OFLX) in urinary tract infections].
The clinical efficacy of the new quinolone antibacterial agent ofloxacin (OFLX) on urinary tract infections (UTI) was reevaluated. A 400-600 mg dose per day of OFLX was administered to 85 adult patients with various kinds of UTI. OFLX was effective clinically in 92.6% of the patients with acute UTI without urinary tract complications. In 81.8% of the patients with chronic complicated UTI because of organic or functional urinary tract disorders, OFLX was effective. This drug also has a marked bacteriological efficacy. No side effects or abnormal laboratory findings were seen in any of the patients administered OFLX.